Cardiovascular Safety Watch Column
This month’s column takes a new approach to reporting about cardiovascular safety issues. It focuses on a paper by Dr David Gutstein and his co-authors, which discusses the drug anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor. J. Rick Turner at Quintiles describeshow cardiovascular safety liabilities associated with an earlier drug in the same class, torcetrapib, are not associated with anacetrapib.
http://jforcs.com/jcs/wp-content/uploads/edd/2012/11/2-Cardiovascular-Safety-Watch-column.pdf